The new effort combines adaptive platform trial design, AI-enabled site activation, nationwide data infrastructure, and patient data contribution tools to reduce timelines, costs, and patient burden across clinical development.
|Articles|May 29, 2014
WIRB-Copernicus Group Launches an Oncology-focused Institutional Review Board
The WIRB-Copernicus Group announced it has formed a new cancer-focused institutional review board, WCG Oncology.
Advertisement
The WIRB-Copernicus Group (WCG), a provider of regulatory and ethical review services for clinical research, announced it has formed a new cancer-focused institutional review board, WCG OncologyTM. WCG Oncology features its Expert Advisory Board, which provides strategic counsel to WCG regarding the changing oncology research landscape, covering cutting-edge theory, scientific methods, technologies, and study designs.
WCG is creating this group because it is a fast-evolving medical fields--featuring advances in gene therapy, targeted treatments, and companion diagnostics. In the past four years, WCG has reviewed more than 4,000 oncology protocols, which have substantially increased in complexity.
WCG Oncology is constituted by three dedicated IRB panels, which focus wholly on the ethical oversight of oncology research, and a cadre of expert oncological specialists to assist in the review of complex and scientifically-challenging research.
Read the full release
Advertisement
Related to this article
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is shifting trial risk management from reactive to proactive—enabling sponsors to pressure-test protocols and anticipate pivots before a single patient is enrolled.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
AI agents in clinical operations acquire broader autonomous capability through expanded permissions, tools, memory, and delegated authority, requiring governance focused on whether effective capability has shifted outside approved boundaries rather than whether software has changed.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
RWE is finding a role earlier in drug development than ever before, but the data quality, integration, and organizational alignment required to make it regulatory-grade are still catching up to the ambition.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains why combining analog trial performance data with real-world patient data and site-level recruitment history gives sponsors a far more honest picture of whether their enrollment assumptions are actually achievable.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials
2
Where AI Leads in Trial Design—and Where Humans Still Need To
3
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
4
What an AI-Informed Approach Means for How Sponsors Think About Risk
5